These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay. Tajik N; Shahsavar F; Nasiri M; Radjabzadeh MF Int J Immunogenet; 2010 Jun; 37(3):159-68. PubMed ID: 20193031 [TBL] [Abstract][Full Text] [Related]
3. Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis. Mahmoudi M; Fallahian F; Sobhani S; Ghoroghi S; Jamshidi A; Poursani S; Dolati M; Hosseinpour Z; Gharibdoost F Clin Rheumatol; 2017 Apr; 36(4):853-862. PubMed ID: 28120169 [TBL] [Abstract][Full Text] [Related]
4. The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis. Tozkır JD; Tozkır H; Gürkan H; Dönmez S; Eker D; Pamuk GE; Pamuk ÖN Clin Rheumatol; 2016 Apr; 35(4):919-25. PubMed ID: 26960450 [TBL] [Abstract][Full Text] [Related]
5. KIR3DL1+HLA-B Bw4Ile80 and KIR2DS1+HLA-C2 combinations are both associated with ankylosing spondylitis in the Iranian population. Tajik N; Shahsavar F; Poormoghim H; Radjabzadeh MF; Mousavi T; Jalali A Int J Immunogenet; 2011 Oct; 38(5):403-9. PubMed ID: 21797986 [TBL] [Abstract][Full Text] [Related]
7. The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate cancer. Roshan Zamir M; Ariafar A; Ghaderi A; Amirzargar A Immunobiology; 2023 Mar; 228(2):152319. PubMed ID: 36599262 [TBL] [Abstract][Full Text] [Related]
8. Positive association of Bx genotype, KIR2L5, KIR2DS5 and full-length KIR2DS4 with the risk of meningioma. Barani S; Taghipour M; Ghaderi A Immunobiology; 2020 Mar; 225(2):151900. PubMed ID: 31899050 [TBL] [Abstract][Full Text] [Related]
9. Association of killer cell immunoglobulin-like receptors and their cognate HLA class I ligands with susceptibility to acute myeloid leukemia in Iranian patients. Mirzazadeh S; Bemani P; Halimi H; Sanaee MN; Karami N; Ramzi M; Farjadian S Sci Rep; 2023 Jul; 13(1):11456. PubMed ID: 37454198 [TBL] [Abstract][Full Text] [Related]
10. Genetic profiles of killer-cell immunoglobulin-like receptors and HLA ligands in Thai blood donors. Kitpoka P; Tammakorn C; Chaisri S; Leelayuwat C; Mongkolsuk T; Thammanichanond D Hum Immunol; 2016 Jun; 77(6):470-5. PubMed ID: 27131859 [TBL] [Abstract][Full Text] [Related]
11. Activating KIR/HLA-I combinations as a risk factor of adult B-ALL. Halimi H; Mirzazadeh S; Kalantar K; Hajimaghsoodi M; Ramzi M; Farjadian S Hum Immunol; 2024 Mar; 85(2):110750. PubMed ID: 38262874 [TBL] [Abstract][Full Text] [Related]
12. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. Sahin U; Dalva K; Gungor F; Ustun C; Beksac M Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412 [TBL] [Abstract][Full Text] [Related]
13. The impact of KIR-HLA genotype on hepatitis B virus clearance in Iranian infected individuals. Shah-Hosseini A; Jafari M; Mohammadi A; Sanaei R; Alavian SM; Doosti-Irani A; Nooradeh Keykavousi M; Tajik N Med Microbiol Immunol; 2017 Dec; 206(6):463-470. PubMed ID: 29032460 [TBL] [Abstract][Full Text] [Related]
14. KIR genes and HLA class I ligands in Gaucher disease. Vairo F; Portela P; Salim PH; Jobim M; Netto C; Dorneles A; Mittlestadt S; Jobim LF; Schwartz IV Gene; 2013 Mar; 516(1):53-7. PubMed ID: 23266622 [TBL] [Abstract][Full Text] [Related]
16. Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma. Keating SE; Ní Chorcora C; Dring MM; Stallings RL; O'Meara A; Gardiner CM Tissue Antigens; 2015 Sep; 86(3):172-7. PubMed ID: 26202659 [TBL] [Abstract][Full Text] [Related]
17. Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group. Jobim MR; Jobim M; Salim PH; Portela P; Jobim LF; Leistner-Segal S; Bittelbrunn AC; Menke CH; Biazús JV; Roesler R; Schwartsmann G Hum Immunol; 2013 Sep; 74(9):1130-3. PubMed ID: 23792055 [TBL] [Abstract][Full Text] [Related]
18. Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study. Varbanova VP; Mihailova S; Naumova E; Mihaylova AP Turk J Haematol; 2019 Nov; 36(4):238-246. PubMed ID: 31337191 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Killer Cell Immunoglobulin-Like Receptor Genes and Their HLA Ligands in Inflammatory Bowel Diseases. Beigmohammadi F; Mahmoudi M; Karami J; Ahmadzadeh N; Ebrahimi-Daryani N; Rezaei N J Immunol Res; 2020; 2020():4873648. PubMed ID: 33015197 [TBL] [Abstract][Full Text] [Related]
20. A study of KIR genes and HLA-C in Vogt-Koyanagi-Harada disease in Saudi Arabia. Sheereen A; Gaafar A; Iqneibi A; Eldali A; Tabbara KF; Adra C; Al-Hussein K Mol Vis; 2011; 17():3523-8. PubMed ID: 22219647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]